Based on the different roles of Smad3 and Smad2 in TGFβ signaling [29], [30] and the fact that Smad3, but not Smad2, mediates the liver fibrosis response [17], we thereby propose that NPLC0393 might supply a promising interest in the treatment of liver fibrosis with high specificity, although the detailed mechanism of such specificity needs to be further investigated. The gene discussed is SMAD2; the disease is Hepatic fibrosis.